Increased density of glutamate receptor subunit 1 due to Cerebrolysin treatment: An immunohistochemical study on aged rats

Histochemical Journal

Volumn 33, Issue 11-12, 2001, Pages 605-612

  Eder, P ^a   Reinprecht, I ^a   Schreiner, E ^a   Skofitsch, G ^b   Windisch, M ^a  

^a JSW Life Sciences GmbH   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CEREBROLYSIN; GLUTAMATE RECEPTOR; PEPTIDE; RECEPTOR ANTIBODY; RECEPTOR SUBUNIT;

AGED; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; CORRELATION ANALYSIS; HIPPOCAMPUS; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEARNING; MAZE TEST; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; SPATIAL MEMORY;

AGING; AMINO ACIDS; ANIMALS; BEHAVIOR, ANIMAL; FEMALE; HIPPOCAMPUS; IMAGE PROCESSING, COMPUTER-ASSISTED; INJECTIONS, INTRAPERITONEAL; MALE; MAZE LEARNING; NEUROPEPTIDES; NOOTROPIC AGENTS; RATS; RATS, LONG-EVANS; RECEPTORS, AMPA; SPACE PERCEPTION;

ANIMALIA;

EID: 0035745610     PISSN: 00182214     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016394031947     Document Type: Article

References (65)

1. Excitatory amino acids and memory: Evidence from research on Alzheimer's disease and behavioral pharmacology
2. Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transection of fimbria-fomix in the rat brain
3. The effects of Cerebrolysin on survival and sprouting of neurones from cerebral hemispheres and from the brainstem of chick embryos in vitro
4. AMPA-selective glutamate receptor subtype immunoreactivity in the hippocampal dentate gyms of patients with Alzheimer disease
5. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease
6. Molecular regulation of the blood-brain barrier GLUT1 glucose transporter reporter by brain derived peptides
7. Brain derived peptides increase the expression of a blood-brain barrier GLUT1 glucose reporter gene
8. In vivo upregulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived peptides
9. Evidence for caspase-mediated cleavage of AMPA receptor subunits in neuronal apoptosis and Alzheimer's disease
10. In vitro autoradiography of hippocampal excitatory amino acid binding in aged Fischer 344 rats: Relationship to performance on the Morris water maze
11. Glutamate metabotropic and AMPA binding sites are reduced in Alzheimer's disease: An autoradiographic study of the hippocampus
12. Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: Short-term study
13. Excitatory amino acid AMPA receptor mRNA localization in several regions of normal and neurological disease affected human bain. An in situ hybridization histochemistry study
14. Glutamate transmission and toxicity in Alzheimer's disease
15. Cerebrolysin, a peptidergic drug, increases performance of ischemic rats in the morris water maze
16. Ameliorative influence of a nootropic drug on motor activity of rats after bilateral carotid artery occlusion
17. The influence of Cerebrolysin and E021 on spatial navigation of 24-month-old rats
18. Early postnatal treatment with peptide preparations influences spatial navigation of young and adult rats
19. The drug Cerebrolysin and its pepfide fraction E021 increase the abundance of the blood-brain barrier GLUT1 glucose transporter in brains of young and old rats
20. Increased binding of BDNF to TrkB induced by the antidementia drug Cerebrolysin
21. Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons
22. Cloned glutamate receptors
23. Effects of AB1-40 on the functions of expressed glutamate receptors and the protective effects of brain derived peptides
24. Dose-dependent behavioural effects of two protein-free peptide derivatives on the passive avoidance reaction of rats
25. Effects of two protein-free peptide derivatives on passive avoidance behaviour of 24-month-old rats
26. Death of cultured telencephalon neurons induced by glutamate is reduced by the peptide derivative Cerebrolysin
27. Further evidence that Cerebrolysin protects cortical neurons from neurodegeneration in vitro
28. Cerebrolysin protects isolated cortical neurons from neurodegeneration after brief hi stotoxic hypoxia
29. Localization of Non-N-Methyl-D-Aspartate Glutamate receptors in normal and Alzheimer Hippocampal Formation
30. Hippocampus
31. Age-related structural changes in the rat hippocampus: Correlation with working memory deficiency
32. Morphological hippocampal changes during normal aging and their relation to cognitive deterioration
33. Excitotoxicity and neuroprotection
34. Interneurons unbound
35. Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging
36. Membrane topology of the GluR1 glutamate receptor subunit: Epitope mapping by site-directed antipeptide antibodies
37. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease
38. Brain-derived neurotrophic factor regulates the expression of AMPA receptor proteins in neocortical neurons
39. In vitro autoradiograpby of ionotropic glutamate receptors in hippocampus and striatum of aged Long-Evans rats: Relationship to spatial learning
40. Neuroreceptor changes in Alzheimer Disease
41. Age-related changes in expression of Ampa-selective glutamate receptor subunits: Is calcium-permeability altered in hippocampal neurons?
42. Metabotropic glutamate receptor agonist (1S,3 R-ACPD) increased frontal cortex dopamine release in aged but not in young rats
43. Open-label study of Cerebrolysin in the treatment of dementia under conditions of daily clinical practice
44. Two peptidergic drugs increase the synaptophysin immunoreactivity in brains of 24-month-old rats
45. Reversible neural inactivation reveals hippocampal participation in several memory processes
46. Efficacy of the peptidergic nootropic drug Cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT)
47. Neurotrophic effects of FPF-1070 (Cerebrolysin) on cultured neurons from chicken embryo dorsal root ganglia, ciliary ganglia and sympathetic trunks
48. Effects of CERE on ECoG during moderate forebrain ischemia under normothermic and hypothermic conditions
49. Physiological effects and brain protection by hypothermia and Cerebrolysin after moderate forebrain ischemia in rats
50. Protective effect of FPF (Cerebrolysin) on delayed neuronal death in the gerbildetection of hydroxyl radicals with salicylic acid
51. Age-related decreases of the N-methyl-D-aspartate receptor complex in the rat cerebral cortex and hippocampus
52. The neuropathology of Alzheimer Disease and the structural basis of its cognitive alterations
53. Synapse alteration in hippocampal CA3 field following entorhinal cortex lesion
54. Mild forms of multi-infarct dementia: Efficacy of cerebrolysin
55. Calcium and neuronal ageing
56. Phenotypic down-regulation of glutamate receptor subunit GluR1 in Alzheimer's disease
57. Effects of post-mortem delay on subunits of ionotropic glutamate receptors in human brain
58. Zur entwicklung der neuronenstruktur der fascia dentata bei der ratte. Neurohistologischmorphometrische, ultrastrukturelle und experimentelle untersuchungen
59. Two peptidergic drugs increase the synaptophysin immunoreactivity in brains of 6-week-old rats
60. The effects of different growth factors in rats after lesions of the somato sensory cortex
61. Neurotrophic activities and therapeutic experience with a brain derived peptide preparation
62. Cerebrolysin enhances the protective effects of MK-801 against neuronal degeneration in vitro
63. The peptide derivative Cerebrolysin inhibits the calcium dependent protease Calpain II
64. Reduction of AMPA-selective glutamate receptor subunits in the entorhinal cortex of patients with Alzheimer's disease pathology: A biochemical study